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Summary 
To determine the role of vascular cell adhesion molecule 1 (VCAM-1) /very late activation antigen 
4 (VLA-4) and intercellular adhesion molecule 1 (ICAM-1)/lymphocyte function-associated antigen 
1 (LFA-1) interactions in causing antigen-induced eosinophil and T  cell recruitment into the 
tissue, we studied the effect of the in vivo blocking of VCAM-1, ICAM-1, VLA-4, and LFA-1 
by pretreatment with monoclonal antibodies (mAb) to these four adhesion molecules on the 
eosinophil and T cell infiltration of the trachea induced by antigen inhalation in mice. The in 
vivo blocking of VCAM-1 and VLA-4, but not of ICAM-1 and LFA-1, prevented antigen-induced 
eosinophil infiltration into the mouse trachea. On the contrary, the in vivo blocking of VCAM-1 
and VLA-4, but not of ICAM-1 and LFA-1, increased blood eosinophil counts after antigen 
challenge,  but did not affect blood eosinophil counts without antigen challenge in sensitized 
mice. Furthermore, the expression of VCAM-1 but not ICAM-1 was strongly induced on the 
endothelium of the trachea after  antigen challenge.  In addition, pretreatment with anti-IL-4 
mAb decreased the antigen-induced VCAM-1 expression only by 27%  and had no significant 
effect on antigen-induced eosinophil infiltration into the trachea. The in vivo blocking of VCAM-1 
and VLA-4 inhibited antigen-induced CD4 + and CD8 + T cell infiltration into the trachea more 
potently than that of ICAM-1 and LFA-1. In contrast, regardless of antigen challenge,  the in 
vivo blocking of LFA-1, but not of ICAM-1, increased blood lymphocyte counts more than 
that of VCAM-1 and VLA-4. These results indicate that VCAM-1/VLA-4 interaction plays a 
predominant role in controlling antigen-induced eosinophil and T cell recruitment into the tissue 
and that the induction of VCAM-1 expression on the endothelium  at the site of allergic inflammation 
regulates  this eosinophil and T  cell recruitment. 
E 
osinophil and T cell infiltration into the tissue is a char- 
acteristic feature of allergic inflammation such as asthma. 
Increasing evidence suggests that the migration of lenkocytes 
into the tissue is controlled by the interaction of ceU-surface 
adhesion molecules between leukocytes and vascular endothelial 
cells (1). In vitro studies have shown that the adhesion of 
eosinoph/ls to vascular endothelial cells and its transendothelial 
migration are mediated by the interactions of intercellular 
adhesion molecule 1 (ICAM-1) 1 and lymphocyte function- 
associated antigen 1 (LFA-1) (2-4) and of vascular cell adhe- 
1 Abbreviations used in this ~per: ICAM-1, intercellular adhesion molecule 
1; LFA-1, lymphocyte function-assodated antigen 1; VCAM-1, vascular 
cell adhesion molecule 1; VLA-4, very late activation antigen 4. 
sion molecule 1 (VCAM-1)  and very late activation antigen 
4 (VLA-4) (5-9). The adherence of T  cells to cultured en- 
dothelial cells and its transendothelial migration are also medi- 
ated by ICAM-1/LFA-1 (10-14) and VCAM-1/LFA-4 (15-17) 
interactions. In addition, it has been reported that the trans- 
endothelial migration of T  cells in vitro is dependent on 
1CAM-1 but not VCAM-1, whereas the adhesion of T cells 
to cultured endothelial cells depends on both ICAM-1 and 
VCAM-1  (18, 19). Furthermore, it  has been shown that 
inflammatory cytokines such as TNF and IL-1 induce ICAM-1 
and VCAM-1 expressions on cultured endothelial cells (20-23) 
and that the adhesion of eosinophils and T cells to cultured 
endothelial ceils is also increased by the stimulation of the 
endothelial cells with these cytokines (2, 5-17, 24-26). IL-4 
has also recently been shown to selectively induce VCAM-1 
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and increase the adherence of eosinophils and T  cells to the 
endothelial cells in vitro (27-29). However, the in vivo func- 
tional importance of ICAM-1/LFA-1 and VCAM-1/VLA-4 
interactions  has  not yet been clarified in causing  antigen- 
induced eosinophil and T  cell recruitment into the tissue. 
Therefore, to elucidate this issue, we studied the effect of the 
in vivo blocking of ICAM-1, VCAM-1, LFA-1, and VLA-4 
using mAbs  to these four adhesion  molecules on antigen- 
induced eosinophil and T  cell recruitment  into the mouse 
airways.  We  also  studied  the  expression  of ICAM-1  and 
VCAM-1 after antigen inhalation in the airways of sensitized 
mice to determine the regulatory role of ICAM-1 and VCAM-1 
expressions at  the site of antigen  challenge in causing  the 
eosinophil and T cell recruitment into the tissue. Our results 
indicate that VCAM-1/VLA-4 interaction plays a predomi- 
nant role in controlling antigen-induced eosinophil and T 
cell recruitment  into  the tissue  and  that  the induction  of 
VCAM-1 expression on the endothelium at the allergic inflam- 
matory site regulates this eosinophil and T  cell recruitment. 
Materials and Methods 
Mice  and  Immunization.  Female  BALB/c  mice  (age  8  wk) 
(Charles River Laboratories,  Atsugi, Japan) were immunized in- 
traperitoneally twice with 1/~g of OVA (Sigma Chemical Co., St. 
Louis, MO) in 4 mg of aluminium hydroxide at a 2-wk interval. 
10-14 d after the second immunization, the sensitized  mice were 
challenged with aerosolized OVA as described below. 
mAbs.  Rat anti-murine VCAM-1 mAb M/K-1 (IgG2b) (30), 
rat anti-murine VLA-4 mAb PS/2 (IgG2b) (31), rat anti-routine 
ICAM-1 mAb YN1/1.7 (IgG2b) (32, 33), rat anti-murine LFA-1 
mAb KBA (IgG2a) (34), and rat anti-routine IL-4  mAb 11.811 (IgG1) 
(35) were used in this study. The rat mAb were purified from as- 
cites produced from the hybridomas with the use of a Protein 
G--Sepharose  4FF  affinity column  (Pharmacia  LKB,  Uppsala, 
Sweden), and all mAbs were used as purified IgG. The mAbs con- 
tained a negligible amount ofendotoxin (<1 pg/mg) as determined 
by the timulns amebo~ lysat~  ~s~y  (Sdhg~u ~gyo Co., Tokyo, 
Japan). 
Antigen.induced Eosinophil Infiltration in Mouse Trachea.  The eo- 
sinophil infiltration into the trachea was induced by the inhalation 
of antigen  in  sensitized  mice,  and  the  number  of eosinophils 
infiltrating into the submucosal tissue of trachea was evaluated as 
described  previously (36). Briefly, the sensitized  mice were indi- 
vidually placed in 50-ml plastic tubes and inhaled with aerosolized 
OVA (50 mg/ml) dissolved in 0.9% saline by a nebulizer (model 
646; DeVilbiss Co., Somerset, PA) for 20 rain. As a control, 0.9% 
saline alone was administered by the nebulizer. At various intervals 
after the inhalation, the mice were killed by cervical dislocation 
and the tracheas were excised. After the tracheas were fixed in 10% 
formalin, the specimens were embedded in paraffin,  sectioned in 
3/~m thick segments, and stained with Luna solution and hemat- 
oxylin-eosin solution. The number ofeosinophils in the submucosal 
tissue of trachea was counted in Luna-stained sections and expressed 
as the number of eosinophils  per length of the basement mem- 
brane of trachea, which was measured with a digital curvimeter. 
The eosinophil infiltration into the trachea of sensitized mice began 
at 6 h after antigen inhalation and reached a peak at 24 h (36). 
Antigen-induced T Cell Infiltration in the Trachea.  T cell infiltra- 
tion into the trachea was assessed by direct staining with strepto- 
avidin-biotinylated  antibody technique as described previously (37). 
Briefly, the trachea was removed and frozen with OCT compound 
(Miles Laboratories, Naperville, IL) in a liquid nitrogen bath. After 
acetone-fixed  cryostat sections  (3/~m  thick) were treated with 
normal rabbit serum, the sections were incubated with biotinylated 
anti-Thy 1.2, anti-L3T4, or anti-Lyt-2 mAb (Becton Dickinson & 
Co., Mountain View, CA) at room temperature for 2 h. As a nega- 
tive control, biotinylated normal rat IgG was used. Sections were 
then incubated with the streptavidin conjugated with horseradish 
peroxidase (Vector Laboratories, Inc., Burlingame, CA) at room 
temperature for 30  rain,  followed by the  reaction with  Y,3- 
diaminobenzidine in Tris-HC1 buffer containing HzO~ for 5 min. 
The immunostained cells were counted and expressed as described 
above. CD4 + and CD8 + T  cell infiltration into the trachea oc- 
curred 2 h after inhalation and reach a peak at 12-24 h  (37). 
Effect of Anti-VCAM-1 and Anti-VLA-4 mAbs.  To determine 
whether VCAM-1 on the endothelial cells is involved in antigen- 
induced eosinophil and T cell recruitment into the tissue, we ex- 
amined the effect of the in vivo administration of anti-VCAM-1 
mAb on antigen-induced eosinophil and T cell infiltration in the 
trachea of sensitized  mice. OVA-sensitized mice were injected in- 
traperitoneally with  1  mg  of rat  anti-murine  VCAM-1  mAb 
(M/K-l) (30) 24 h before the inhaled OVA challenge. As a control, 
OVA-sensitized mice were injected intraperitoneally with purified 
rat IgG (1 rag) (Jackson ImmunoResearch Laboratories, West Grove, 
PA) 24 h before the inhaled OVA challenge.  The eosinophil and 
T cell infiltration into the trachea was evaluated at 24 h after OVA 
inhalation. 
Since VLA-4 is a counter-receptor for VCAM-1  (16) and is ex- 
pressed on eosinophils and lymphocytes but not on neutrophils (5-8, 
38), we also examined the effect of anti-VLA-4 mAb on antigen- 
induced eosinophil and T cell infiltration in the trachea of sensi- 
tized mice. Rat anti-routine VLA-4 mAb (PS/2) (1 rag) (31) or 
purified rat IgG (1 mg) was injected intraperitoneally 24 h before 
the inhaled OVA challenge.  The eosinophil and T cell infiltration 
into the trachea was evaluated  at 24 h  after OVA inhalation. 
Effect of Anti-ICAM-1  and Anti-LFA-I  mAbs.  To determine 
whether ICAM-1 on the endothelial ceils is involved in antigen- 
induced eosinophil and T cell recruitment into the tissue, we ex- 
amined the effect of the in vivo administration of anti-ICAM-1 
mAb on antigen-induced eosinophil and T cell infiltration in the 
trachea of sensitized  mice.  We also examined the effect of mAb 
to LFA-1, which is a ligand for ICAM-1 (39), on the antigen-induced 
eosinophil and T  cell infiltration. OVA-sensitized  mice were in- 
jected intraperitoneally with rat anti-murine ICAM-1 mAb (YN1/ 
1.7) (1 rag) (32, 33), rat anti-murine LFA-1 mAb (KBA) (1 mg) 
(34), or purified rat IgG (1 rag) 24 h before the inhaled OVA chal- 
lenge. The eosinophil and T cell infiltration into the trachea was 
evaluated  at 24 h after OVA inhalation. 
VCAM-1 and ICAM-1 Expression in the Trachea.  The expres- 
sion of VCAM-1 and ICAM-1 on the endothelium of the trachea 
was assessed at 24 h after OVA inhalation by the immunocytochem- 
ical staining using optimally diluted biotinylated anti-VCAM-1 mAb 
(M/K-l), anti-ICAM-1  mAb (YN1/1.7), and rat IgG (negative con- 
trol) as described above. The intensity of staining was classified 
according to the criteria as described  by Briscoe et al. (40). The 
VCAM-1 and ICAM-1 expression on the endothelium was evalu- 
ated as score 0 (absent  staining or faint staining of an occasional 
vessel only), 1+  (faint staining of several vessds),  2+  (moderate 
intensity staining of most vessels), and 3 +  (intense staining of most 
vessels). The sections were coded and then examined by two ob- 
servers in a blind manner, and the average of the two determina- 
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VCAM-1 or ICAM-1 expression. 
Because ID4 has been shown to upregnhte the expression of 
VCAM-1 but not ICAM-1 on cttltured endothelial cells (23) and 
thereby enhance eosinophil migration in vitro (27, 28), we also 
examined the effect  of anti-Ib4 mAb on antigen-induced VCAM-1 
expression and eosinophil infiltration in the trachea of sensitized 
mice. OVA-sensitized mice were injected intraperitoneally with 
anti-murine IL-4 mAb (11Bll) (5 rag) (35) or purified rat IgG (5 
rag) 24 h before the inhaled OVA challenge. In preliminary experi- 
ments, greater than 2 mg of anti-IL-4 mAb completely prevented 
anti-OVA IgE production in BALB/c mice assessed by passive cu- 
taneous anaphylaxis  reaction. The VCAM-1 expression and eosin- 
ophil infiltration in the trachea was evaluated at 24 h after OVA 
inhalation. In addition, a significant  amount of anti-IL-4 mAb was 
detectable (600-710 #g/ml), which was assessed  by an ELISA  using 
anti-rat IgG, in the mouse serum at the time of OVA inhalation. 
Data Analysis.  Data  are  summarized as mean  +_  SD.  The 
statistical analysis of the results was performed by the analysis of 
variance using Fisher's least significant difference  test for multiple 
comparisons, p <0.05 was considered significant. 
Results 
Effect of  In Vi~ Blocking of VCAM-I and VLA-4 on Anage.- 
induced Eosinophil  Infiltration  into the Mouse  Trachea.  The 
in vivo blocking of VCAM-1  by pretreatment with anti- 
VCAM-1 mAb decreased the eosinophil infiltration induced 
by antigen inhalation in the trachea of sensitized mice. The 
intraperitoneal preinjection with anti-VCAM-1 mAb (M/K-l; 
1 mg) 24 h before the inhaled OVA challenge significantly 
decreased OVA-induced eosinophil infiltration into the tra- 
chea of OVA-sensitized  mice at 24 h by 73%  (control rat 
IgG  21.4  _+  3.2  vs.  anti-VCAM-1  mAb  5.7  _+  1.2  eo- 
sinophils/mm, mean  _+  SD,  n  =  10 mice in each group, 
p <0.001) (Fig. 1). In addition, the eosinophil infiltration into 
the trachea of OVA-sensitized  mice was negligible at 24 h 
after saline inhalation (0.21 +  0.16 eosinophils/mm, n  =  10). 
The in vivo blocking of VLA.4, a ligand of VCAM-1, 
by pretreatment with anti-VLA-4 mAb also decreased antigen- 
induced eosinophil infiltration in the mouse trachea. The in- 
traperitoneal preinjection with anti-VLA-4 mAb (PS/2;  1 
rag) 24 h before the inhaled OVA challenge significantly de- 
creased OVA-induced eosinophil infiltration into the trachea 
at 24 h by 74% (n  =  10, iv <0.001) (Fig.  1). The preventive 
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Figure  1.  Effect of  in  vivo 
blocking  of  VCAM-1 and VLA-4 
on antigen-induced  eosinophil  in- 
filtration  in mouse  trachea. OVA- 
sensitized BALB/c mice were 
injected intraperitoneally with 
anti-murine  VCAM-1  mAb 
(M/K-l),  anti-murine VLA-4 
mAb (PS/2), or rat IgG 24 h be- 
fore inhaled  OVA challenge,  and 
the  number  of  eosinophils 
infiltrating into the submucosal 
tissue of trachea was then counted at 24 h after OVA inhalation. Data 
are means + SD for 10 mice in each group. "Significantly  different  from 
the mean value of the control response (rat IgG), p <0.001. 
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Figure  2.  Effect of  in  vivo 
blocking  of  VCAM-1 and VLA-4 
on antigen-induced  T cell  infiltra- 
tion in  mouse trachea. CD4 + 
(top) and CD8 + (bouora) T call 
infiltration  in the trachea  was ex- 
amined  at 24 h. Experimental  pro- 
tocols are the same  in Fig. 1. Data 
are means _+ SD for 10 mice in 
each group. "Significantly  dif- 
ferent from the mean value of 
the control response (rat IgG), 
p <0.001. 
effect of  combination ofanti-VCAM-1 mAb (M/K-l; 1 rag) 
and anti-VLA-4 mAb (PS/2; 1 rag) was at a similar degree 
of decrement when pretreated with anti-VCAM-1 mAb or 
anti-VLA-4 mAb alone (Fig.  1). 
Effect of In Vivo Blocking of VCAM-1 and VLA-4 on Antigen- 
induced T Cell Infiltration into the Trachea.  The in vivo blocking 
of VCAM-1 decreased antigen-induced T cell infiltration (both 
CD4 + T cells and CD8 + T cells) in the mouse trachea. The 
preinjection with anti-VCAM-1 mAb significantly decreased 
OVA-induced CD4 + T  cell infiltration into the trachea at 
24 h by 78% (control rat IgG 2.51  _+ 0.53 vs. anti-VCAM-1 
mAb 0.56  _  0.11 CD4 + T  cells/mm, n  =  10, p <0.001) 
(Fig.  2).  The  preinjection with anti-VCAM-1  mAb  also 
significantly decreased OVA-induced CD8 + T  cell infiltra- 
tion into the trachea at 24 h by 78% (control rat IgG 0.65 
_+  0.13  vs.  anti-VCAM-1  mAb  0.15  _  0.03  CD8 +  T 
cells/mm, n  --  10, p  <0.001)  (Fig.  2). 
The in vivo blocking of VLA.4 also decreased  antigen- 
induced T  cell infiltration in the trachea. The preinjection 
with anti-VLA-4 mAb significantly  decreased OVA-induced 
CD4 + T  cell infiltration into the trachea by 24 h by 75% 
(n  =  10, p  <0.001)  (Fig.  2).  The preinjection with anti- 
VLA.4  mAb  also  significantly  decreased  OVA-induced 
CD8 + T  cell infiltration into the trachea at 24 h by 72% 
(n  -  10, p  <0.001)  (Fig.  2).  The combined effect of anti- 
VCAM-1 mAb and anti-VLA-4 mAb was at a similar degree 
of decrement when pretreated with anti-VCAM-1 mAb or 
anti-VLA.4 mAb alone (Fig.  2). 
Effect of In Vivo Blocking of lCAM-1 and LFA-1 on Antigen- 
induced Eosinophil Infiltration into the Trachea.  In contrast, the 
in vivo blocking of ICAM-1  by pretreatment with anti- 
ICAM-1 mAb (YN1/1.7; 1 mg) had no significant effect on 
antigen-induced eosinophil infiltration in the trachea of sen- 
sitized mice at 24 h (n  =  10) (Fig. 3). The in vivo blocking 
of LFA-1, a ligand of ICAM-1, by pretreatment with anti- 
LFA-1  mAb  (KBA;  1 mg)  did not  significantly decrease 
antigen-induced eosinophil infiltration into the trachea at 24 h, 
either (n  =  10)  (Fig.  3). 
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Figure  3.  Effect  of  in  vivo 
blocking of ICAM-1 and LFA-1 
on antigen-induced eosinophil in- 
filtration in mouse trachea. OVA- 
sensitized mice were injected in- 
traperitoneally with anti-routine 
ICAM-1 mAb (YN1/1.7), anti- 
murine LFA-1 mAb (KBA), or rat 
IgG 24 h before OVA inhalation, 
and the eosinophil infiltration in 
the trachea was examined at 24 h. 
Data are means _+ SD for 10 mice 
in each group. 
Effect of  In Vivo Blocking of  lCAM-1 and LFA-1 on Antigen- 
induced T Cell Infiltration into the Trachea.  The in vivo blocking 
of ICAM-1 decreased antigen-induced T  cell infiltration  in 
the mouse trachea. The preinjection with anti-ICAM-1 mAb 
significantly decreased OVA-induced CD4 + T  cell infiltra- 
tion into the trachea at 24 h by 44% (control rat IgG 2.45 
_+  0.54  vs.  anti-ICAM-1  mAb  1.38  _+  0.25  CD4 +  T 
cells/mm, n  =  10, p <0.001) (Fig. 4). The preinjection with 
anti-ICAM-1 mAb also significantly decreased OVA-induced 
CD8 + T  ceil infiltration  into  the trachea at 24 h by 51% 
(control rat IgG 0.66  _  0.19 vs.  anti-ICAM-1  mAb 0.32 
_+  0.05  CD8 + T  cells/mm,  n  =  10, p  <0.001)  (Fig.  4). 
The  in vivo blocking of LFA-1 also decreased antigen- 
induced T  cell infiltration  in the trachea.  The preinjection 
with anti-LFA-1 mAb signiiicantly decreased OVA-induced 
CD4 + T  cell infiltration  into the trachea at 24 h by 50% 
(n  =  10, p <0.001) (Fig. 4). The preinjection with anti-LFA-1 
mAb also significantly decreased OVA-induced CD8 + T  cell 
infiltration into the trachea at 24 h by 50% (n =  10, P <0.001) 
(Fig.  4). The combination of anti-ICAM-1  mAb and anti- 
LFA-1 mAb decreased OVA-induced CD4 + and CD8 + T 
cell infiltration into the trachea at 24 h by 62 and 65%, respec- 
tively, but these degrees of decrement were not significantly 
different from that of anti-ICAM-1 mAb or anti-LFA-1 mAb 
alone (Fig.  4). 
Dose-response Curves of raAbs to VCAM-1, ICAM-1,  VLA-4, 
and LFA-1 in Antigen-induced Eosinophil and T Cell Infiltration 
into the Trachea.  To determine whether the amounts (1 mg, 
each) of mAb to the four adhesion molecules are sufl~dent 
to inhibit  antigen-induced  eosinophil infiltration  in mouse 
trachea,  we examined  dose-response curves of these mAb 
(0.5-4 rag), which were administered intraperitoneally 24 h 
before the inhaled antigen challenge, in antigen-induced eo- 
sinophil infiltration in the trachea of sensitized mice. We also 
examined dose-response curves of mAbs to ICAM-1 and LFA- 1 
in antigen-induced T cell infiltration in the trachea. The in- 
hibitory effects of these four mAb on the antigen-induced 
eosinophil and CD4 + T  cell infiltration  at 24 h  were not 
significantly different at 0.5,  1,  and 4 mg of mAbs tested 
(n  =  5 mice in each group)  (Fig.  5). 
Effect of Combined Blocking of Both VCAM-1 and ICAM-1 
on Antigen-induced Eosinophil and T Cell Infiltration into the Tra- 
chea.  There  was no  significant  additive  effect of in  vivo 
blocking of both VCAM-1 and ICAM-1 on antigen-induced 
eosinophil infiltration  into  the trachea.  The decrement  of 
antigen-indueed  eosinophil infiltration  at 24 h by pretreat- 
ment with both anti-VCAM-1 mAb (M/K-l; 1 mg) and anti- 
ICAM-1 mAb (YN1/1.7;  1 rag) was similar to that of anti- 
VCAM-1 mAb alone (n  =  10, each) (Fig.  6). 
However, the combination of anti-VLA-4 mAb (PS/2;  1 
mg)  and  anti-LFA-1  mAb  (KBA;  1  rag)  more  potently 
prevented antigen-induced eosinophil infiltration at 24 h than 
anti-VLA-4 mAb alone (control rat IgG 20.1  _+ 3.2 vs. anti- 
VLA-4 mAb 5.3 _  1.1 vs. combination ofanti-VLA-4 mAb 
and anti-LFA-1 mAb 0.7  _+  0.3 eosinophils/mm,  n  =  10, 
F <0.001)  (Fig.  6), although  anti-LFA-1 mAb had no fig- 
nificant  effect (Figs.  3  and 6). 
In contrast to antigen-induced eosinophil infiltration,  the 
combination of anti-VCAM-1 mAb and anti-ICAM-1 mAb 
inhibited antigen-induced CD4 + and CD8 + T cell infiltra- 
tion at 24 h more potently than anti-VCAM-1 mAb alone 
(n  =  8, each, p  <0.01) (Fig.  7). The combination of anti- 
VLA-4 mAb and anti-LFA-1 mAb also decreased antigen- 
induced CD4 + and CD8 + T  cell infiltration  at 24 h  more 
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Figure  4.  Effect  of  in  vivo  lo 
blocking of ICAM-1 and LFA-1  sJ  ~--~  | 
on antigen-induced T cell infiltra-  0 |t  ........ 
tion  in  mouse  trachea.  CD4 +  0  ~  2  3  4 
infiltration in the trachea was ex-  ~ 
amined at 24 h. Experimental pro-  ~ 
tocols are the same in Fig. 3. Data  ~ 
are means  •  SD for 10 mice in 
each  group.  *Significantly  dif- 
ferent  from  the mean value  of 
the control response (rat IgG),  0  1  ~  ~  4 
p  <0.001.  mat) (rag) 
Figure  S.  Dose-responsecurves 
of  monoclonal  antibodies  to 
VCAM-1, ICAM-1, VLA-4, and 
LFA-1 in antigen-induced eosin- 
ophil and T  cell  inf~tration in 
mouse  trachea.  OVA-sensitized 
mice  were  injected intrapedto- 
neally with 0.5,  1,  or 4  mg of 
anti-VCAM-1  mAb  (i),  anti- 
ICAM-1 mAb (0),  anti-VLA-4 
mAb (D),  or  anti-LFA-1  mAb 
(O) 24 h before OVA inhalation, 
and  the  eosinophil  (top) and 
CD4 § T cell (bottom) infihration 
in the trad~ was eam~ed at 24 h. 
Control  OVA-sensitized  mice 
were  injected  intraperitoneally 
with 4 mg of rat lgG. Data are 
means +_ SD for five mice in each 
group. 
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Figure 6.  Effect of combined blocking of both VCAM-1 and ICAM-1 
on antigen-induced eosinophil infiltration in mouse trachea. OVA-sensitized 
mice were injected intraperitoneally with anti-VCAM-1 mAb, anti-ICAM-1 
mAb, the combination of anti-VCAM-1 mAb and anti-ICAM-1 mAb, anti- 
VLA-4 mAb, anti-LFA-1 mAb, the combination of anti-VLA-4 mAb and 
anti-LFA-1 mAb, or rat IgG 24 h before OVA inhalation,  and the eosino- 
phil infiltration  in the trachea was examined at 24 h. Data are means  • 
SD for 10 mice in each group.  "Significantly different from the mean value 
of the control response (rat IgG), p <0.001.  "Significantly different from 
the mean value of the response by anti-VLA-4 mAb pretreatment, p <0.001. 
potently than anti-VLA-4 mAb alone (n =  8, each, p <0.01) 
(Fig.  7). 
Effect of In Vivo Blocking of VCAM-1/VLA-4 and ICAM- 
1/LFA-I on Blood Leukocyte Counts.  The in vivo blocking 
of VCAM-1 and VLA-4, but not of ICAM-1 and LFA-1, 
increased blood eosinophil counts after antigen challenge in 
sensitized mice. The preinjection with anti-VCAM-1 mAb 
and anti-VLA-4 mAb significantly increased blood eosino- 
phil counts at 24 h after OVA inhalation by 211 and 186%, 
respectively, (control rat IgG 94 •  26 vs. anti-VCAM-1 mAb 
292  •  63 vs. anti-VLA-4 mAb 269  •  76 eosinophils/mm  3, 
iiill i  , 
011llil/  
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Figure  7.  Effect of combined blocking of both VCAM-1 and ICAM-1 
on antigen-induced  T cell infiltration in mouse trachea. CD4 + (top) and 
CD8 + (bottom) T cell infiltration in the trachea was examined at 24 h. 
Experimental protocols are the same in Fig. 6. Data are means  •  SD for 
eight mice in each group.  "Significantly  different from the mean value 
of the control response (rat IgG), p <0.001.  *'Significantly different from 
the mean value of the response by anti-VCAM-1 mAb or anti-VLA-4 mAb 
pretreatment, p  <0.01. 
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Figure 8.  Effect of in vivo blocking of VCAM-1/VLA-4 and ICAM- 
1/LFA-1 on blood cosinophil counts in mice. OVA-sensitized mice were 
injected intraperitoneally with anti-VCAM-1 mAb, anti-VLA-4 mAb, anti- 
ICAM-1 mAb, anti-LFA-1 mAb, the combinations of these mAb, or rat 
IgG 24 h before OVA inhalation,  and blood eosinophil counts were exam- 
ined at 24 h after OVA inhalation.  Data are means  •  SD for 10 mice 
in each group.  *Significantly different from the mean value of the control 
response (rat  lgG), p <0.001. 
n  =  10, p <0.001), whereas the in vivo blocking of ICAM-1 
or LFA-1 did not significantly affect blood eosinophil counts 
(n =  10, each) (Fig. 8). Furthermore, the combined blocking 
of VCAM-1 and ICAM-1 increased blood eosinophil counts 
more potently than that of VCAM-1 alone (combination of 
anti-VCAM-1  and anti-ICAM-1  444  +  122  eosinophils/ 
mm  3, n  =  10, p  <0.01)  (Fig.  8).  The combined blocking 
of VLA-4 and LFA-1 also increased blood eosinophil counts 
more potently than that of VLA-4 alone (combination of 
anti-VLA-4  and  anti-LFA-1  752  _+  171  eosinophils/ 
mm  3, n  =  10, p  <0.001)  (Fig.  8).  In contrast, the in vivo 
blocking of VCAM-1 and VLA-4 did not significantly in- 
crease blood eosinophil counts after the inhalation of saline 
in sensitized mice (data not shown). The combined blocking 
of VCAM-1 and ICAM-1 and of VLA-4 and LFA-1 had no 
effect on blood eosinophil counts after saline inhalation in 
sensitized mice, either (data not shown). 
The in vivo blocking of LFA-1 increased blood lympho- 
cyte counts at 24 h after antigen challenge in sensitized mice 
by 99% (control rat IgG 3303  _+  481 vs. anti-LFA-1 mAb 
6559  •  664 lymphocytes/mm  3, n  =  10, p <0.001), whereas 
the in vivo blocking of ICAM-1 did not significantly increase 
blood lymphocyte counts (Fig.  9). The in vivo blocking of 
Control 
a-ICAM 
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(x-ICAM  +  (~.-I.FA 
a-VCAM 
a-VIA 
a-VCAM +  a-VIA 
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D 
-'1 
I** 
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Blood Lymphocyte Counts (per mm  3) 
Figure 9.  Effect of in vivo blocking of VCAM-1/VLA-4 and ICAM- 
1/LFA-1 on blood lymphocyte counts in mice. Experimental protocols are 
the same in Fig. 8, and blood lymphocyte counts were examined at 24 h 
after OVA inhalation.  Data are means  +  SD for 10 mice in each group. 
*,  "'Significantly different from the mean value of the control response 
(rat  IgG),  "p <0.01,  **p <0.001. 
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by 45 and 41%, respectively (n  =  10, each, p <0.01) (Fig. 
9). The combined blocking of VCAM-1 and ICAM-1 and 
of VLA-4 and LFA-1 also increased blood lymphocyte  count  s 
by 129 and 538%, respectively (n =  10, each,/~ <0.001) (Fig. 
9). In addition, these increases in blood lymphocyte counts 
were similarly observed after the inhalation of saline in sensi- 
tized mice (data not shown). 
Antigen-induced VCAM-1 and ICAM-1 Expression on the En- 
dothelium of the Trachea.  ICAM-1 was expressed moderately 
and universally on the endothdium in the trachea of sensi- 
tized mice before the inhaled OVA challenge, and ICAM-1 
expression on the endothelium was not significantly increased 
at 24 h after the inhaled OVA challenge (ICAM-1 score; sa- 
line inhalation 2.26  _+ 0.28 vs. inhaled OVA challenge 2.66 
_+  0.39, n  =  5) (Fig.  10). In contrast, VCAM-1 was not 
significantly expressed on the endothelium in the trachea be- 
fore antigen challenge. However, VCAM-1 expression on the 
endothelium was strongly increased at 24 h after antigen chal- 
lenge (VCAM-1 score; saline inhalation 0.20 +  0.18 vs. in- 
haled OVA challenge 1.73 _+ 0.27, n =  5,p <0.001) (Fig. 10). 
Pretreatment with anti-IL-4 mAb (11Bll; 5 mg) decreased 
antigen-induced VCAM-1 expression on the endothelium only 
by 27%  (n  =  5, p <0.02) (Fig.  10). In contrast, anti-IL-4 
mAb did not significantly affect ICAM-1 expression on the 
endothelium (Fig. 10). The pretreatment with anti-IL-4 mAb 
did not significantly affect antigen-induced  eosinophil infiltra- 
tion in the trachea,  either (n  =  10, data not shown). 
Discussion 
In this study, we show that VCAM-1/VLA-4 interaction 
plays a predominant role in controlling antigen-induced eo- 
sinophil recruitment into the tissue. We found that the in 
vivo blocking of VCAM-1 and VLA-4, but not of ICAM-1 
and LFA-1, prevented antigen-induced eosinophil infiltration 
into the mouse trachea (Figs. I and 3). We also found that, 
on the contrary, the in vivo blocking of VCAM-1 and VLA-4, 
but not of ICAM-1 and LFA-1, increased blood eosinophil 
0- 
Saline  Antigen  oblL-,4 
challenge  +  Ar~gen 
challenge 
~p<0.001 
P<0"001-'I I-  -" p<0"02"-] I 
Saline 
challenge  Antigen 
challenge 
Figure  10.  Antigen-induced 
VCAM-1 and ICAM-1 expression 
on the endothelium  of mouse tra- 
chea. The e~pression of VCAM-1 
and ICAM-1 on the endothdium 
of the trachea was assessed at 24 h 
after OVA or saline inhalation by 
the immunocytochemical staining 
using biotinyhted anti-VCAM-1 
mAb and anti-ICAM-1 mAb. The 
intensity  of  staining  was  then 
scored according to the criteria as 
described  in  Materials  and 
Methods.  A group of sensitized 
mice was also injected intraperi- 
toneally  with  anti-murine  Ib4 
mAb (111311) 24 h before the in- 
haled  OVA challenge.  Data  are 
means + SD for five mice in each 
group. 
counts at 24 h after antigen challenge (Fig. 8). In addition, 
the in vivo blocking of VCAM-1 and VLA-4, however, did 
not increase blood eosinophil counts without inhaled antigen 
challenge in sensitized mice. Furthermore, the expression of 
VCAM-1 but not ICAM-1 was found to be strongly induced 
on the endothelium of the trachea after inhaled antigen chal- 
lenge (Fig.  10). Taken together, these results indicate that 
VCAM-1/VLA-4 interaction mediates antigen-induced eo- 
sinophil recruitment into the tissue and that the induction 
of VCAM-1 expression on the endothelium at the allergic 
inflammatory site regulates  this eosinophil recruitment. 
In vitro studies previously showed that both ICAM-1/ 
LFA-1 (2-4) and VCAM-1/VLA-4 (5-9) interactions were 
involved in the adhesion of eosinophils to vascular endothelial 
cells and its transendothelial migration. It was also shown 
that there was an additive effect of CDll/CD18-dependent 
pathway and VCAM-l-dependent pathway on eosinophil ad- 
herence to cultured endothelial cells (5, 9). However, the in 
vivo importance of these adhesion molecules has not been 
evaluated in antigen-induced eosinophil recruitment into the 
tissue. Our present study shows that ICAM-1/LFA-1 inter- 
action is not significantly involved in causing antigen-induced 
eosinophil recruitment into the tissue (Fig. 3).  Wegner et 
al. (41) demonstrated that pretreatment with anti-ICAM-I 
mAb prevented eosinophil migration into the bronchoalveolar 
lavage fluid in monkeys. Their finding is in disagreement with 
our present observation and might be due to the interference 
of epithelial  ICAM-1 and subsequent inhibition of eosino- 
phil migration from the mucosal side of airways to the lu- 
minal side because ICAM-1 is expressed on airway epithe- 
lium as well as endothelium (41). However, our findings that 
the combined blocking of VCAM-1 and ICAM-1 and of 
VLA-4 and LFA-1 had greater effects on blood eosinophil 
counts than that of VCAM-1 or VLA-4 alone (Fig. 8) sug- 
gest that ICAM-1/LFA-1 interaction might exert a minor 
role in antigen-induced eosinophil recruitment into the tissue 
when VCAM-1/VLA-4 interaction is blocked. Furthermore, 
the finding that the combined blocking of VI.A-4 and LFA-1 
increased  blood  eosinophil  counts  greater  than  that  of 
VCAM-1 and ICAM-1 (Fig. 8) also suggests a possible in- 
volvement of LFA-1/ICAM-2 interaction in the antigen- 
induced eosinophil recruitment because ICAM-2 has been 
shown to be another ligand for LFA-1 (42,  43). 
We demonstrate that antigen inhalation induces VCAM-1 
expression on the endothelium at a site of antigen challenge 
in sensitized mice (Fig. 10), indicating that antigen-induced 
VCAM-1  expression  on endothelial cells is  an important 
regulatory step of antigen-induced eosinophil migration into 
the tissue.  It has been shown that inflammatory cytokines 
such as TNF and IL-1 induce VCAM-1 expression on cul- 
tured endothelial cells in vitro (22, 23) and on the endothelium 
in the skin in vivo (40) and that the adhesion of eosinophils 
to cultured endothelial cells is also increased by the stimula- 
tion of the endothelial cells with these cytokines (5-9). Fur- 
thermore, IL-4 has recently been shown to selectively induce 
VCAM-1 but not ICAM-1 expression on cultured endothelial 
cells (23) and increase eosinophil adherence to the endothelial 
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IL-4 in antigen-induced VCAM-1 expression in the trachea. 
We found that pretreatment with anti-IL-4 mAb decreased 
the antigen-induced VCAM-1 expression only by 27% (Fig. 
10). In addition, pretreatment of anti-IL-4 mAb had no 
significant  effect on antigen-induced eosinophil infiltration 
into the trachea, which is shown to be dependent on VCAM- 
1/VLA-4 interaction (Fig. 1). These results suggest that other 
cytokines such as IL-1 and TNF-ol as well as IL-4 might be 
important in causing antigen-induced VCAM-1 expression 
on the endothelium  of the airways. Briscoe et al. (40) reported 
that the intradermal injection of IL-4 induced little or no 
VCAM-1 expression on the endothelium but enhanced TNF- 
induced VCAM-1 expression,  which is consistent with our 
present observation. 
Second, we also show that VCAM-1/VLA-4 interaction 
is functionally predominant over ICAM-1/LFA-1 interaction 
in controlling antigen-induced T  cell recruitment into the 
tissue, as indicated by the finding that the in vivo blocking 
of VCAM-1 and VLA-4 inhibited antigenqnduced CD4 + 
and CD8 + T  cell infiltration into the mouse trachea more 
potently than that of ICAM-1 and LFA-1 (Figs. 2, 4, and 
7). Previous studies showed that ICAM-1/LFA-1 interaction 
(10-14) and VCAM-1/VLA-4 interaction (15-17) were in- 
volved in the adherence  of T  cells to endothelial cells and 
its transendothelial migration in vitro. Our finding of inhi- 
bition  of antigen-induced T  cell  recruitment by in vivo 
blocking of VCAM-1 and VLA-4 (Fig. 2) is consistent with 
the in vitro observation by Dustin and Springer (13) that 
the adhesion of T cells to cytokine-stimulated  endothelial cells 
is mostly mediated through an LFA-l-independent pathway. 
Our finding of the involvement of ICAM-1 and LFA-1 in 
antigen-induced T cell recruitment (Fig. 4) is also consistent 
with their finding that T cell adherence to cytokine-stimulated 
endothelial cells is partially mediated by ICAM-1/LFA-1 in- 
teraction (13). The interference of ICAM-1/LFA-1 interac- 
tion in vivo might also inhibit initial T cell activation during 
the antigen presentation because ICAM-1 has been shown 
to contribute to antigen-independent adhesion between T 
cells and antigen-presenting cells (44).  In contrast to our 
findings, it has recently been reported that ICAM-1 plays 
a prominent role in the transendothelial migration of T cells 
in vitro, whereas VCAM-1 does not significantly mediate the 
migration (18, 19). The reason for this discordance in the 
role of VCAM-1 and ICAM-1 in T cell migration is unclear 
and might be explained by a possible contribution of the in- 
teraction between VLA-4 and fibronectin in the matrix in vivo. 
There has been a recent observation that memory T cells 
selectively traffic from blood to peripheral tissues to lymph 
nodes via afferent lymph vessels, whereas naive T cells selec- 
tively traffic from blood to lymph nodes via high endothelial 
venules (45).  It has also been shown that memory T  cells 
have increased levels of LFA-1 and VLA-4 expressions com- 
pared with naive T cells (46, 47). Therefore, in addition to 
the induction of VCAM-1 and ICAM-1 expressions on the 
endothelium, it is possible that the increased expression of 
LFA-1 and VLA-1 on memory T cells might also contribute 
to the T cell infiltration into the airways. Indeed, memory 
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T cells show stronger adhesion to cytokine-stimulated cul- 
tured endothelial cells than naive T  cells (48). 
We have also found that the in vivo blocking of LFA-1, 
but not of ICAM-1, increases blood lymphocyte counts (Fig. 
9), suggesting that an LFA-l-dependent, ICAM- 1-indepen- 
dent basal adhesion, which was not significantly affected by 
cytokines (13), operates basal lymphocyte redrculation in vivo. 
In contrast, as already mentioned, our results indicate that 
the extravasation  of lymphocytes to the tissue is operated 
through an LFA-1- and IGAM-l-dependent pathway (Fig. 
4), which was previously shown to be strongly upregulated 
by cytokines (13), as well as VGAM-1/VLA-4 interaction (Fig. 
2). It has been shown that in vitro adherence oflymphocytes 
to high endothelial venules of peripheral lymph nodes is sub- 
stantially inhibited by anti-LFA-1 mAb (49, 50) and that the 
administration of anti-LFA-1  mAb decreases the migration 
of normal lymphocytes into lymph nodes and Peyer's patches 
by 40-60%  (49).  The difference in the effects of in vivo 
blocking of LFA-1 and ICAM-1 on blood lymphocyte counts 
suggests a possible involvement of LFA-1/ICAM-2 interac- 
tion in basal lymphocyte  redrcuhtion in vivo because ICAM-2 
is another ligand for LFA-1 (42, 43) and LFA-l-dependent 
binding of lymphocytes to endothelium has been shown to 
be totally accounted for by ICAM-1 and ICAM-2 (51). Con- 
sistent with this possibility, it has been shown that anti-ICAM-1 
mAb does not inhibit the binding of lymphocytes to high 
endothelial venules  (52).  Our finding that  the combined 
blocking of VLA-4 and LFA-1 increased blood lymphocyte 
counts greater than that of VCAM-1 and ICAM-1 (Fig. 9) 
might also be explained by a possible involvement of LFA- 
1/ICAM-2 interaction when VCAM-1/VLA-4 interaction 
is blocked. 
In addition,  our finding that  the in vivo blocking of 
VCAM-1 and VLA-4 increased blood lymphocyte counts less 
than that of LFA-1 (Fig. 9) suggests that the contribution 
of VCAM-1/VLA-4 interaction to lymphocyte recirculation 
in vivo is relatively small. In vitro adherence of lymphocytes 
to high endothelial venules of Peyer's patches, but not of pe- 
ripheral lymph nodes, has also been shown to be strongly 
inhibited by anti-VLA-4 mAb (53).  The increase in blood 
lymphocyte counts by in vivo blocking of VCAM-1  and 
VLA-4 might also be due to the release of lymphocytes from 
the bone marrow by the interference of attachment of lym- 
phocytes to stroma cells because VCAM-1/VLA-4 interac- 
tion has been shown to be important in binding of lympho- 
cytes to bone marrow stroma cells (30). 
Our results show that the most prominent difference be- 
tween antigen-induced T cell and eosinophil recruitments is 
the dependence of ICAM-1/LFA-1 interaction in T cell recruit- 
ment and the independence of this interaction in eosinophil 
recruitment (Fig. 3 and 4). There might be a difference in 
the ratio of cell surface expression of LFA-1 and VLA-4 be- 
tween T cells and eosinophils. Another possible explanation 
is that the blocking of ICAM-1/LFA-1 interaction might in- 
hibit subsequent T cell activation by antigen-presenting ceils 
(44) at the same time that it inhibits T cell migration through 
vascular endothelial cells. 
Eosinophil infiltrate is a characteristic  feature of allergic inflammation  such as asthma.  Increasing evidence suggests 
that  the infiltrating eosinophils cause the tissue damage of 
the airways and airway hyperreactivity by releasing the cyto- 
toxic granules and lipid mediators (54). Therefore, our finding 
of an  important  role  of VCAM-1/VLA-4  interaction  in 
antigen-induced eosinophil recruitment into the airways sug- 
gests that the interference with VCAM-1/VLA-4 interaction 
by a specific  antagonist  for the adhesion molecules and by 
a specific antisense oligonudeotide for the mKNA would be 
a potential  therapeutic  approach to control airway inflam- 
mation of asthma.  Indeed, it has been reported that a syn- 
thetic  peptide  can  specifically  interfere  with  the  binding 
of VLA-4  to its ligand  (55).  It has  also been shown that 
the expression of a cell surface adhesion  molecule on  the 
endothelium can be inhibited by an antisense oligonucleo- 
tide (56). 
In summary, we have shown that VCAM-1/VLA-4 inter- 
action plays a predominant role in controlling antigen-induced 
eosinophil and T  cell recruitment  into the tissue and that 
the induction  of VCAM-1 expression on the endothelium 
at the allergic inflammatory site regulates this eosinophil and 
T  cell recruitment.  These results  suggest that  antagonism 
of VCAM-1/VLA-4  interaction  would be a rational  ther- 
apeutic  approach  to  allergic  airway  inflammation  such  as 
asthma. 
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